ID: ALA432738

Max Phase: Preclinical

Molecular Formula: C16H14Cl2N6O

Molecular Weight: 377.24

Molecule Type: Small molecule

Representations

Canonical SMILES:  CCNC(=O)Nc1nc2nc(N)ncc2cc1-c1c(Cl)cccc1Cl

Standard InChI:  InChI=1S/C16H14Cl2N6O/c1-2-20-16(25)24-14-9(12-10(17)4-3-5-11(12)18)6-8-7-21-15(19)23-13(8)22-14/h3-7H,2H2,1H3,(H4,19,20,21,22,23,24,25)

Standard InChI Key:  BXEDCNVFSZUBPI-UHFFFAOYSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 377.24

Molecular Weight (Monoisotopic): 376.0606

AlogP: 3.72

#Rotatable Bonds: 3

Polar Surface Area: 105.82

Molecular Species: NEUTRAL

HBA: 5

HBD: 3

#RO5 Violations: 0

HBA (Lipinski): 7

HBD (Lipinski): 4

#RO5 Violations (Lipinski): 0

CX Acidic pKa: 11.49

CX Basic pKa: 4.44

CX LogP: 3.32

CX LogD: 3.32

Aromatic Rings: 3

Heavy Atoms: 25

QED Weighted: 0.65

Np Likeness Score: -1.10

References

1. Hamby JM, Connolly CJ, Schroeder MC, Winters RT, Showalter HD, Panek RL, Major TC, Olsewski B, Ryan MJ, Dahring T, Lu GH, Keiser J, Amar A, Shen C, Kraker AJ, Slintak V, Nelson JM, Fry DW, Bradford L, Hallak H, Doherty AM..  (1997)  Structure-activity relationships for a novel series of pyrido[2,3-d]pyrimidine tyrosine kinase inhibitors.,  40  (15): [PMID:9240345] [10.1021/jm970367n]

2. Thompson AM, Connolly CJ, Hamby JM, Boushelle S, Hartl BG, Amar AM, Kraker AJ, Driscoll DL, Steinkampf RW, Patmore SJ, Vincent PW, Roberts BJ, Elliott WL, Klohs W, Leopold WR, Showalter HD, Denny WA..  (2000)  3-(3,5-Dimethoxyphenyl)-1,6-naphthyridine-2,7-diamines and related 2-urea derivatives are potent and selective inhibitors of the FGF receptor-1 tyrosine kinase.,  43  (22): [PMID:11063616] [10.1021/jm000161d]

Source

Source(1):

• Scientific Literature